Zobrazeno 1 - 5
of 5
pro vyhledávání: '"I. Shchendrigin"'
Publikováno v:
European Journal of Preventive Cardiology. 28
Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): State Task Introduction. Assessment of vascular age (VA), based on the determination of the arterial stiffness (AS), is attracting mor
Autor:
E. Gubar, T. Korotaeva, Y. Korsakova, E. Loginova, L. Vorobyova, S. Glukhova, E. Nasonov, V. Sorotskaya, I. Kushnir, I. Shchendrigin, I. Umnova, P. Shesternya
Publikováno v:
Annals of the Rheumatic Diseases. 81:1592.2-1593
BackgroundThe latest data show that psoriatic arthritis (PsA) patients (pts) with asymmetrical sacroiliitis (SI) have clinical and genetic features which are considered typical for PsA (1).ObjectivesTo analyze comparative clinical characteristics of
Autor:
E. Loginova, T. Korotaeva, E. Gubar, Y. Korsakova, S. Glukhova, E. Nasonov, V. Sorotskaya, I. Patrikeeva, P. Shesternya, I. Shchendrigin
Publikováno v:
Annals of the Rheumatic Diseases. 81:867-867
BackgroundPsoriatic arthritis (PsA) is a disease with multidomain clinical presentation such as arthritis, enthesitis, dactylitis, spondylitis and psoriasis (PsO). [1]. Enthesitis is a key clinical feature of PsA with significant impact on function,
Autor:
V. Sorotskaya, Nasonov El, N. Kuznetsova, Tatiana Korotaeva, Irina Umnova, M. Chamurlieva, Y. Korsakova, Elena Loginova, I. Shchendrigin, E. Gubar, I. Patrikeeva, Svetlana Glukhova
Publikováno v:
Annals of the Rheumatic Diseases. 80:1325.2-1326
Background:Psoriatic arthritis (PsA) is heterogeneous in its clinical presentation and disease course, but many patients (pts) develop a destructive form of arthritis. Psoriasis (PsO) precedes arthritis by an average of 7 years. [1]. Theory of transi
Autor:
R. Samigullina, N. Kiryukhina, T. Salnikova, T. Rasevich, Nasonov El, E. Kalinina, I. Semizarova, I. Bashkova, D. Kretchikova, D. Bobrikova, I. Vinogradova, V. Sorotskaya, E. Koltsova, A. Dyo, I. Shchendrigin, O. Semagina, A. Dadalova, M. Semchenkova, D. Murtazalieva, Alexander Lila, V. Mazurov, D. Chakieva, A. Davydova, I. Shafieva, A. Baranov, N. Lapkina, I. M. Marusenko, I. Kushnir, A. Karateev
Publikováno v:
Annals of the Rheumatic Diseases. 80:1095.3-1096
Background:JAK inhibitors block intracellular signaling pathways responsible for the synthesis of cytokines and mediators involved in the development of chronic pain and central sensitization (CS). This determines a very rapid clinical response to JA